Labeling with gallium-68

Benjamin P. Burke; Stephen J. Archibald

doi:10.1002/9781119500575.ch9

Labeling with gallium-68

Benjamin P. Burke^*, Stephen J. Archibald

^*Corresponding author for this work

Imaging Chemistry & Biology

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

7 Citations (Scopus)

Abstract

Gallium-68 has seen the largest growth in nuclear medicine usage of any isotope over the past 10 years. To design an ideal chelator for ⁶⁸Ga, a range of criteria need to be met: fast radiolabeling, quantitative incorporation, mild radiolabeling conditions, low precursor concentration (high molar activity), metal ion selectivity, versatile and robust conjugation chemistry, and high in vivo stability. The development of ⁶⁸Ga-radiopharmaceuticals is arguably the fastest-moving area in nuclear medicine, emerging from research studies 10 years ago to become the gold standard for some clinical situations. This chapter provides an overview of the key clinical ⁶⁸Ga-radiopharmaceuticals and their principal applications, followed by details of their respective radiosyntheses. The presence of ethanol in ⁶⁸Ga radiosynthesis seems to improve reaction efficiency, even when compared with aqueous solutions, potentially via radiolysis stabilization by scavenging of free radicals.

Original language	English
Title of host publication	Handbook of Radiopharmaceuticals
Subtitle of host publication	Methodology and Applications: Second Edition
Publisher	WILEY-BLACKWELL
Pages	291-323
Number of pages	33
ISBN (Electronic)	9781119500575
ISBN (Print)	9781119500544
DOIs	https://doi.org/10.1002/9781119500575.ch9
Publication status	Published - 9 Jan 2021

Keywords

Clinical situations
Conjugation chemistry
Gallium-68
Radiolabeling
Radiopharmaceuticals
Radiosynthesis
Theranostic applications

Access to Document

10.1002/9781119500575.ch9

Cite this

@inbook{60a668d938ec4d4785b4fcdb9a7fdad4,

title = "Labeling with gallium-68",

abstract = "Gallium-68 has seen the largest growth in nuclear medicine usage of any isotope over the past 10 years. To design an ideal chelator for 68Ga, a range of criteria need to be met: fast radiolabeling, quantitative incorporation, mild radiolabeling conditions, low precursor concentration (high molar activity), metal ion selectivity, versatile and robust conjugation chemistry, and high in vivo stability. The development of 68Ga-radiopharmaceuticals is arguably the fastest-moving area in nuclear medicine, emerging from research studies 10 years ago to become the gold standard for some clinical situations. This chapter provides an overview of the key clinical 68Ga-radiopharmaceuticals and their principal applications, followed by details of their respective radiosyntheses. The presence of ethanol in 68Ga radiosynthesis seems to improve reaction efficiency, even when compared with aqueous solutions, potentially via radiolysis stabilization by scavenging of free radicals.",

keywords = "Clinical situations, Conjugation chemistry, Gallium-68, Radiolabeling, Radiopharmaceuticals, Radiosynthesis, Theranostic applications",

author = "Burke, {Benjamin P.} and Archibald, {Stephen J.}",

note = "Publisher Copyright: {\textcopyright} 2021 John Wiley & Sons Ltd.",

year = "2021",

month = jan,

day = "9",

doi = "10.1002/9781119500575.ch9",

language = "English",

isbn = "9781119500544",

pages = "291--323",

booktitle = "Handbook of Radiopharmaceuticals",

publisher = "WILEY-BLACKWELL",

}

TY - CHAP

T1 - Labeling with gallium-68

AU - Burke, Benjamin P.

AU - Archibald, Stephen J.

PY - 2021/1/9

Y1 - 2021/1/9

N2 - Gallium-68 has seen the largest growth in nuclear medicine usage of any isotope over the past 10 years. To design an ideal chelator for 68Ga, a range of criteria need to be met: fast radiolabeling, quantitative incorporation, mild radiolabeling conditions, low precursor concentration (high molar activity), metal ion selectivity, versatile and robust conjugation chemistry, and high in vivo stability. The development of 68Ga-radiopharmaceuticals is arguably the fastest-moving area in nuclear medicine, emerging from research studies 10 years ago to become the gold standard for some clinical situations. This chapter provides an overview of the key clinical 68Ga-radiopharmaceuticals and their principal applications, followed by details of their respective radiosyntheses. The presence of ethanol in 68Ga radiosynthesis seems to improve reaction efficiency, even when compared with aqueous solutions, potentially via radiolysis stabilization by scavenging of free radicals.

AB - Gallium-68 has seen the largest growth in nuclear medicine usage of any isotope over the past 10 years. To design an ideal chelator for 68Ga, a range of criteria need to be met: fast radiolabeling, quantitative incorporation, mild radiolabeling conditions, low precursor concentration (high molar activity), metal ion selectivity, versatile and robust conjugation chemistry, and high in vivo stability. The development of 68Ga-radiopharmaceuticals is arguably the fastest-moving area in nuclear medicine, emerging from research studies 10 years ago to become the gold standard for some clinical situations. This chapter provides an overview of the key clinical 68Ga-radiopharmaceuticals and their principal applications, followed by details of their respective radiosyntheses. The presence of ethanol in 68Ga radiosynthesis seems to improve reaction efficiency, even when compared with aqueous solutions, potentially via radiolysis stabilization by scavenging of free radicals.

KW - Clinical situations

KW - Conjugation chemistry

KW - Gallium-68

KW - Radiolabeling

KW - Radiopharmaceuticals

KW - Radiosynthesis

KW - Theranostic applications

UR - http://www.scopus.com/inward/record.url?scp=85136946293&partnerID=8YFLogxK

U2 - 10.1002/9781119500575.ch9

DO - 10.1002/9781119500575.ch9

M3 - Chapter

AN - SCOPUS:85136946293

SN - 9781119500544

SP - 291

EP - 323

BT - Handbook of Radiopharmaceuticals

PB - WILEY-BLACKWELL

ER -

Labeling with gallium-68

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this